Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuropace Inc (NQ: NPCE )

4.080 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 136
Open 4.080
Bid (Size) 3.760 (1)
Ask (Size) 4.530 (1)
Prev. Close 4.080
Today's Range 4.080 - 4.080
52wk Range 1.220 - 9.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Looking Into NeuroPace's Return On Capital Employed
 
Via Benzinga
Dow Jumps Over 300 Points; S&P 500 Rises 1.5%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Friday. The Dow traded up 1.03% to 33,343.73 while the NASDAQ rose 1.92% to 11,682.86. The S&P... 
Via Benzinga

Performance

YTD
+183.33%
+183.33%
1 Month
-17.91%
-17.91%
3 Month
+204.48%
+204.48%
6 Month
+28.71%
+28.71%
1 Year
-51.20%
-51.20%

More News

Read More
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
NeuroPace Earnings Preview
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Nasdaq Up 150 Points; Crude Oil Rises 1%
Via Benzinga
NeuroPace Reports Fourth Quarter & Full Year 2022 Financial Results
From NeuroPace, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
Via Benzinga
NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
From NeuroPace, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors
From NeuroPace, Inc.
Via Globe NewsWire
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference
From NeuroPace, Inc.
Via Globe NewsWire
NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway
From NeuroPace, Inc.
Via Business Wire
$10 Million Bet On Canoo? Check Out These 3 Stocks Under $3 Insiders Are Buying
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update
From NeuroPace, Inc.
Via Globe NewsWire
NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference
From NeuroPace, Inc.
Via Globe NewsWire
NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022
From NeuroPace, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)
From NeuroPace, Inc.
Via Business Wire
NeuroPace's Return On Capital Employed Insights
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.